Brielle Benyon

Lenvatinib/Pembrolizumab Combo Improves Survival, Responses in Advanced Endometrial Cancer

September 11th 2022

Lenvatinib plus pembrolizumab maintained clinically meaningful benefits in outcomes vs physician’s choice of therapy for patients with advanced endometrial cancer who received prior platinum-based chemotherapy.

Tiragolumab and Atezolizumab Plus Chemotherapy Fails to Improve Survival Outcomes in Extensive-Stage SCLC

June 5th 2022

Tiragolumab combined with atezolizumab plus carboplatin and etoposide demonstrated no additional survival benefits compared with atezolizumab plus chemotherapy alone in patients with treatment-naïve, extensive-stage small cell lung cancer.

Lenvatinib Plus Pembrolizumab Improves PFS2 Outcomes in Advanced RCC

June 5th 2022

Patients with advanced renal cell carcinoma who received lenvatinib plus pembrolizumab experienced a longer time to progression on next line of therapy compared with those who received sunitinib.

Daratumumab Plus RVd Demonstrates Durable MRD Negativity in Multiple Myeloma

June 5th 2022

Daratumumab plus induction/consolidation lenalidomide, bortezomib, and dexamethasone elicited higher minimal residual disease-negativity rates vs the RVd combination alone in patients with transplant-eligible newly diagnosed multiple myeloma, including those in high-risk subgroups.

Pacritinib Offers Safe and Tolerable Treatment Option for Patients With Myelofibrosis

June 4th 2022

Treatment with pacritinib demonstrated a comparable safety profile to best available therapies for the treatment of patients with myelofibrosis.

Bringing Creativity to Science: Dawn L. Hershman Is a Giant of Cancer Care

April 1st 2022

For Dawn Hershman, MD, MS, research and medicine are art forms that she uses to uplift and inspire every day.

Long-Term Data Show That Tivozanib Continues to Be Superior Vs Sorafenib in mRCC

February 19th 2022

Follow-up from the TIVO-3 trial showed that patients with pretreated relapsed/refractory renal cell carcinoma who received tivozanib were 5 times more likely to experience long-term progression-free survival compared with sorafenib.

Frontline Tivozanib Is Effective, Safe in Real-World Treatment of mRCC

February 19th 2022

Frontline tivozanib was noninferior to other tyrosine kinase inhibitors for the treatment of patients with metastatic renal cell carcinoma in a real-world setting.

Interventions Needed to Improve QoL, Reduce Psychological Distress in Patients With Myeloma

December 14th 2021

Prognostic awareness was associated with higher rates of psychosocial distress and symptom burden, and lower quality of life in patients with multiple myeloma.

Naratuximab Emtansine Plus Rituximab Serves Unmet Need in Relapsed/Refractory DLBCL Treatment

December 13th 2021

Naratuximab emtansine plus rituximab had promising response rates while also improving patient well-being when used to treat diffuse relapsed/refractory large B-cell lymphoma and other non-Hodgkin B-cell lymphomas.

Depression, Anxiety Affect Patient Perceptions of Cancer Clinical Trials

December 12th 2021

Depression and anxiety can play a significant role in how patients with cancer view cancer clinical trials, ultimately leading to low enrollment

Trastuzumab Duocarmazine Shows PFS Benefit in Pretreated, HER2+ Metastatic Breast Cancer

September 19th 2021

Vic-trastuzumab duocarmazine yielded an improved progression-free survival over standard physician’s choice chemotherapy in patients with pretreated HER2-positive locally advanced or metastatic breast cancer.

Cabozantinib Demonstrates Real-World OS Benefit in Second-Line RCC

September 18th 2021

Cabozantinib as a second-line treatment showed improved overall survival outcomes compared with second-line axitinib in patients with advanced renal cell carcinoma.

Clinical Response to Sotorasib May Vary By Genomic Profile in NSCLC

September 14th 2021

The clinical response to sotorasib could vary in patients with KRAS G12C–mutated non–small cell lung cancer depending on their co-mutational status.

With More At-Home Treatments Available, Importance of Medication Adherence Must Be Stressed

August 9th 2021

With more oral cancer therapies available, the importance of medication adherence and education must be recognized.

Early Intervention For Neurotoxicity Can Improve Outcomes With Cilta-Cel in Relapsed/Refractory Multiple Myeloma

June 13th 2021

Neurologic adverse effect associated with CAR T-cell therapies like ciltacabtagene autoleucel can be managed without long-term lasting effects, as long as they are caught and treated promptly in patients with relapsed/refractory multiple myeloma.

Subcutaneous Elranatamab Elicits Encouraging Responses in Relapsed/Refractory Myeloma

June 8th 2021

The BCMA-targeting humanized bispecific monoclonal antibody elranatamab elicited high response rates when subcutaneously delivered at higher doses in patients with relapsed/refractory multiple myeloma.

Acalabrutinib is Better Tolerated, Noninferior to Ibrutinib in Previously Treated CLL

June 7th 2021

Larotrectinib Demonstrates Promising Responses in NTRK-Fusion+ CNS Tumors

June 7th 2021

Larotrectinib has demonstrated efficacious responses and disease control in patients with TRK fusion–positive central nervous system tumors.

Frontline Nivolumab Plus Ipilimumab or Chemo Improves Survival Outcomes in Advanced ESCC

June 3rd 2021

The addition of nivolumab to either ipilimumab or chemotherapy resulted in improved survival outcomes vs chemotherapy alone in the frontline treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.